UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 7, 2022

CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

001-36279

75-3175693

Delaware (State or other jurisdiction of incorporation)

4 Stamford Plaza 107 Elm Street, 9th Floor Stamford, Connecticut (Address of principal executive offices) (Commission File Number) (IRS Employer Identification No.)

> **06902** (Zip Code)

Registrant's telephone number, including area code (203) 406-3700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

		Name of each exchange on which	
Title of each class	Trading Symbol	registered	l
Common Stock, par value \$0.001 per share	CARA	The Nasdaq Stock Market LLC	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01. Regulation FD Disclosure.

On November 7, 2022, Cara Therapeutics, Inc. (the "Company") made available an updated corporate presentation, which can be found on the Company's website (the "Corporate Presentation"). The Corporate Presentation is furnished as Exhibit 99.1 and incorporated by reference in this Item 7.01.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission ("SEC") under the Exchange Act or the Securities Act of 1933, as amended, (the "Securities Act") whether made before or after the date hereof, regardless of any general incorporation language in such a filing. The information shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description <u>99.1</u> 104 Corporate Presentation, dated November 7, 2022 Cover page interactive data file (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARA THERAPEUTICS, INC.

By: /s/ CHRISTOPHER POSNER Christopher Posner Chief Executive Officer

Date: November 7, 2022



Cara Therapeutics

NOVEMBER 2022



Forward Looking Statements

Statements contained in this presentation regarding matters that are not historical facts are "forward-looking state the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking state statements concerning the Company's ability to successfully commercialize KORSUVA injection and Kapruvia, f and profit share from sales of KORSUVA and Kapruvia, planned future regulatory submissions and potential fut approvals, the performance of the Company's commercial partners, including CSL Vifor, expected timing of enrollment and data readouts from the Company's planned and ongoing clinical trials, the potential results of o trials, timing of future regulatory and development milestones for the Company's product candidates, the po Company's product candidates to be alternatives in the therapeutic areas investigated, including NP, and the po difelikefalin to address additional pruritic indications, the size and growth of the potential markets for pruritus man the Company's expected cash reach. Because such statements are subject to risks and uncertainties, actual res materially from those expressed or implied by such forward-looking statements. These risks and uncertainties ir risks inherent in the launch of new products, including that our commercial partners, including CSL Vifor, may r expected, risks inherent in the clinical and regulatory development of pharmaceutical products, and the risks de fully in Cara Therapeutics' filings with the Securities and Exchange Commission, including the "Risk Factors" Company's Annual Report on Form 10-K for the year ending December 31, 2021 and its other documents subs with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended S 2022. All forward-looking statements contained in this presentation speak only as of the date on which they wer Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances t the date on which they were made, except as required by law.

OUR MISSION:


Transform the way pruritus is treated to bring quality to the lives of those who suffer.

Millions of US patients could benefit from a chron pruritus therapy

		Estimated US Pruritis Pc
	HD-Dependent Chronic Kidney Disease (CKD) ¹⁻²	20(
SYSTEMIC	Non-Dialysis Dependent CKD (Stage 4-5) ³⁻⁷	30(
	Chronic Liver Disease ⁸⁻¹²	31
	Atopic Dermatitis ¹³⁻¹⁵	12
	Notalgia Paresthetica ¹⁶⁻¹⁹	>65

1..National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. 2. Pisoni et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPP Nephrology Dialysis Transplantation (2006); 21(12): 3495-3505. 3. Centers for Disease Control and Prevention https://ncd.cdc.gov/ck/ddetal.asp/?Cnum=Q372.4. DataMonitor 5. States Renal Data System https://adr.usrds.org/2020/chronic-kidney-disease/1-ckd-h-the-general-population. 6. Wong SJY et al. Decisions about Renal Replacement Therapy in Patients with Advanced Kidney Disease in the US Department of Veterans Affairs, 2000–2011. Clin Journal of Am Soc Nepril. 2016. 11(10): 1025-1033. T. Stuku N et al. Pruritus and patient reporte outcomes in non-dialysis (CKD. Clin J. Am Soc Nepril.2) 673-681. 2. Centers for Disease Control and Prevention https://www.cd.gov/chr.Statatal/liver-disease. 11th: 9. Cline State Renal Data System https://statu.usrds.org/2020/chronic-kidney-disease/1-ckd-h-the-general-outcomes in non-dialysis (CKD. Clin J. Am Soc Nepril.2) 673-681. 2. Centers for Disease Control and Prevention https://www.cd.gov/chr.Statatal/liver-disease 1th: 9. Clone State and Dirutus in patients with chronic liver disease. Chronic liver disease and serum autotaxin levels in patients with primary bilary cholangitis. BMC Gastroenterology. 2019. 19:169. 11. Yoshikawa et al. Pruritus is common in patients with chronic liver disease and simproved by natituratine hydrocholinde. Scientific Reports. 2021. 11:3015. 12. Data on file. 13. National Eczema Association. https://mationaleczema.org/eczema/types-of-eczema/type

Cara is well positioned to seize the opportunity ar drive significant immediate and future growth



KORSUVA Injection is poised for rapid uptake



6 | Korsuva is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Limitations of Use Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population

KORSUVA Injection addresses significant unmet I in US CKD-aP hemodialysis market



40%

Patients on hemodialysis¹⁻²

With moderate-severe pruritus²

~200 Addressable Man

National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease.
 URSDS. https://adr.usrds.org/2021/end-stage-renal-disease/1-incidence-prevalence-patient-characteristics-and-treatment-modalities
 Pisoni et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation (2006); 21(12): 3495-3505.

Concentrated dialysis market dynamics provides potential for rapid uptake



 Fresenius Medical Care and DaVita have a combined market share of ~75%¹





- Medicare covers ~80% of CKD-HD patients²
- 2nd drug in TDAPA
 1st drug Parsabiv \$1.4B revenue in 3-yr period³



1. https://healthcareappraisers.com/2020-outlook-dialysis-clinics-and-esrd/

8 2. https://adr.usrds.org/2020/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd 3. Amgen Annual Report 2018, 2019, 2020

Partnership with CSL Vifor can maximize launch r





Leading commercial nephrology organization with turnkey infrastructure, including 100+ sales FTEs




Strong relationships with US nephrology offices and dialysis centers, including joint-venture with Fresenius Medical Care*



Contractual economics bring near term profitability for KORSUVA Injection

9 Vifor has contracted the sales force of Fresenius Renal Pharmaceuticals, a division of Fresenius Medical Care North America, to complement its sales force in selling into Fresenius clinics in the U.S. CSL Limited completed its acquisition of Vifor Pharma AG in August 2022.

KORSUVA injection U.S. launch commenced in Ap 2022 and is progressing well



U.S. KORSUVA Injection Sales



65 mcg/1.3 mL (50 mcg/mL)

Q2 2022

Q3 2022

KORSUVA Net Sales*: \$16.8 million

Profit-Sharing Revenue**: \$8.0 million

Vial Shipments***: 1,812

KORSUVA Net Sales*: \$16.2 mil

Profit-Sharing Revenue**: \$7.4 m

Vial Shipments***: 184,440

* KORSUVA Net Sales: shipment from Vifor to wholesaler


** Profit-Sharing Revenue: Net Revenues - COGS - % Sales & Marketing Fee

Profit Split: 50:50 Cara/Fresenius in Fresenius clinics; 60:40 Cara/Fresenius in non-Fresenius clinics

***Vial Shipments: Shipment from wholesaler to clinics


11 |

Difelikefalin MOA has potentially broad applicatio



Difelikefalin blocks itch response agnostic of itch trigger

Oral difelikefalin has potential for long-term grow




1. Matterne U. et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based crosssectional study. Acta Derm Venereol. 2011;91(6):674-9.2. Matterne U et al. 13 | Incidence and determinants of chronic pruritus: a population-based cohort study. Acta Derm Venereol. 2013;93(5):532-7. 3. Adapted from: Stander S. et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol 2007. 87: 291-294.

Advancing our late-stage pipeline in multiple indications

		STAGE OF DEVELOPMENT			
Program	Indication PRURITUS	Phase 1	Phase 2		
KORSUVA ^R Injection ¹	HD-CKD				
Oral difelikefalin	Advanced NDD-CKD (stages IV-V)				
	Atopic Dermatitis				
	Notalgia Paresthetica				
	Primary Biliary Cholangitis				

1. Approved in the EU and UK with the tradename Kapruvia^R, 2. Commercialization rights to difelikefalin in defined indications - Japan: Maruishi Pharmaceutical Co, LTD; South Korea: Chong Kun Dang 14 Pharmaceuticals. 3. Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has commercial rights under a profit-share arrangement in the US and a royalty arrangement ex-US. HD-CKD: Hemodialysis Chronic Kidney Disease; NDD-CKD: Non-Dialysis Dependent Chronic Kidney Disease


Oral difelikefalin: expanding reach in non-dialysis CKD market



1. Makar M et al. Chronic kidney disease associated pruritus: a review. Kidney Blood Press Res 2021. 46:659-669. 2. Centers for Disease Control and Prevention

15 | https://nccd.cdc.gov/ckd/detail.aspx?Qnum=Q372. 3. DataMonitor 4. States Renal Data System https://adr.usrds.org/2020/chronic-kidney-disease/1-ckd-in-the-general-population. 5. Wong SJY et al. Decisions about Renal Replacement Therapy in Patients with Advanced Kidney Disease in the US Department of Veterans Affairs, 2000–2011. Clin Journal of Am Soc Neprol. 2016. 11(10): 1825-1833. 6. Sukul N et al. Pruritus and patient reported outcomes in non-dialysis CKD. Clin J Am Soc Neprol 2019. 673-681. 7. Mettang T and Kremer AE. Uremic Pruritus. Kidney International. 2015. 87:685-691

Phase 2 data provides path forward into Phase 3 NDD-CKD



- Significant difference achieve 1mg oral difelikefalin and plac NRS score at Week 12
- Generally well-tolerated with a profile consistent with clinica development program
- Phase 2 findings and EOP2 di with FDA established dose an population in Advanced CKD trial

16 |


KICK 1 & KICK 2: Patient Population

STUDY PATIENT POPULATION

- Adults with advanced stage 4 and 5 CKD
- Chronic Pruritus for at least 6 months prior to screening
- Moderate to Severe Pruritus at Baseline (WI-NRS ≥ 5)
- Allowed to be on stable treatment for itch including antihistamines and gabapentinoids


STAGE 1	STAGE 2	STAGE 3	STAGE 4	S	
Normal	Increased Risk	Kidney Damage	Reduced Function	Kidr	
Non Dialysis Dependent					
			Oral		
			Difelikefalin (KICK trials)		

17 | KICK1 US sites only, KICK 2 US and ex-US sites




18 | KICK1 US sites only, KICK 2 US and ex-US sites

Oral difelikefalin: potential to address significant need for an oral antipruritic in atopic dermatitis (A



Correale CE et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician. 1999. 60(4):1191-1198 2. Silverberg JI et al. Patient burden and quality of life in atopic dermatitis in US adults. Annals of Allergy, Asthma, and Immunology (2018). 121(3): 340-347 3. Legat FJ. Itch in atopic dermatitis – what is new? Front Med (Lausanne) 2021. 8:844760. 4. National Eczema Association.
 10 <u>https://nationaleczema.org/eczema/topic-dermatitis</u>/ 5. DRG Analysis. 6. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? *Clin Rev Allergy Immunol.* (2016) 51:263–92. 7. Lipman et al. Current clinical options for the management of itch in atopic dermatitis. Clin Cosmet Investig Dermatol. 2021. 14:959-969 8. Kapur S et al. Atopic dermatitis. Allergy Asthma and Clin Immunol. 2018. 14(Suppl2):52.

KARE STUDY: Phase 2 data in Atopic Dermatitis (



- Anti-pruritic effect started at we was sustained through week 12
- Statistical significance achieved registration endpoint (4-point re in mild-to-moderate AD populati
- The drug was generally well tole

20 |

KIND 1 & KIND 2: Patient Population

STUDY PATIENT POPULATION

- Adults with AD-related pruritus not adequately controlled by topical therapy alone
- Chronic AD-related Pruritus ≥6 weeks
- Moderate to Severe Pruritus at Baseline $(I-NRS \ge 5)$
- Mild to severe Atopic Dermatitis:
 - IGA ≥ 2, BSA ≤20%
- Patients need to be washed out of any medication that may impact itch and/or AD prior to screening
- Stratification to BSA <10% and \geq 10%


Target Enrollment

15% Patient Population BSA ≥10%


85% Patient Population BSA <10%

21 |

KIND 1 Part A: Study Design




22 | KIND 1 Part A will include sites in North America only




23 KIND 1 Part B will include sites in North America only, while KIND 2 will include sites in North America and outside of North America

Oral difelikefalin: potential to address significant need in Notalgia Paresthetica (NP)



24 1. Howard M et al. Notalgia paresthetica: a review for dermatologists. Int J of Derm. 2017. 388-392. 2. US Census Bureau 2020 population projection; 3. Pereira P. et al., Acta DV 2018; 98:82-88; 4. Mollanazar N.K. et al., Acta Clin Croat 2018; 57:721-725; 5. Syneos Health qualitative primary research of US dermatologists, Feb 2022; 5. Syneos market research and Apollo claims database

Encouraging Phase 2 Data in First Well Controlled NP Study



- Significant difference achieved k
 2 mg BID oral difelikefalin and pl in WI-NRS score at Week 8
- Rapid onset of action within Wee sustained response through Wee
- ✓ Significantly greater proportion patients on difelikefalin with ≥ 4improvement starting Week 2
- Generally well-tolerated with saf profile consistent with other clin development programs

25 | LS Means from MMRM with terms for treatment, week, treatment by week interaction, and baseline WI-NRS score Missing data imputed using multiple imputation (MI) under missing at random (MAR) assumption

Strong financial foundation to advance pipeline, e long-term growth

Cash runway into 1st half 2024



• This guidance assumes a level of Korsuva profit share revenue consistent with Q3 '22 actual

\$180M cash position September 30, 2022

- 54M shares outstanding and no debt
- We do not expect to incur commercial costs related to KORSUVA Injec or Kapruvia

IJ


 $\overline{\mathbf{\cdot}}$

Continued pipeline growth

• We have the resources to continue development of the oral difelikefalin platforms

26 |

2022 Milestones and Potential Future Value Cataly Drive Long-term Growth



THANK YOU